Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-06-2017 | Review Article

Imaging the DNA damage response with PET and SPECT

Authors: James C. Knight, Sofia Koustoulidou, Bart Cornelissen

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2017

Abstract

DNA integrity is constantly challenged by endogenous and exogenous factors that can alter the DNA sequence, leading to mutagenesis, aberrant transcriptional activity, and cytotoxicity. Left unrepaired, damaged DNA can ultimately lead to the development of cancer. To overcome this threat, a series of complex mechanisms collectively known as the DNA damage response (DDR) are able to detect the various types of DNA damage that can occur and stimulate the appropriate repair process. Each DNA damage repair pathway leads to the recruitment, upregulation, or activation of specific proteins within the nucleus, which, in some cases, can represent attractive targets for molecular imaging. Given the well-established involvement of DDR during tumorigenesis and cancer therapy, the ability to monitor these repair processes non-invasively using nuclear imaging techniques may facilitate the earlier detection of cancer and may also assist in monitoring response to DNA damaging treatment. This review article aims to provide an overview of recent efforts to develop PET and SPECT radiotracers for imaging of DNA damage repair proteins.

Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–8. http://www.nature.com/nature/journal/v461/n7267/suppinfo/nature08467_S1.html.PubMedPubMedCentralCrossRef

Hoeijmakers JHJ. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475–85. doi:10.1056/NEJMra0804615.PubMedCrossRef

Sirbu BM, Cortez D. DNA damage response: three levels of dna repair regulation. Cold Spring Harb Perspect Biol. 2013;5(8). doi:10.1101/cshperspect.a012724.

Brenerman BM, Illuzzi JL, Wilson DM. Base excision repair capacity in informing healthspan. Carcinogenesis. 2014;35(12):2643–52. doi:10.1093/carcin/bgu225.PubMedPubMedCentralCrossRef

Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287–94.PubMedCrossRef

Li X, Xu H, Xu C, Lin M, Song X, Yi F, et al. The Yin-Yang of DNA damage response: roles in tumorigenesis and cellular senescence. Int J Mol Sci. 2013;14(2):2431–48. doi:10.3390/ijms14022431.PubMedPubMedCentralCrossRef

Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319(5868):1352–5. doi:10.1126/science.1140735.PubMedCrossRef

Koorstra JBM, Hong SM, Shi C, Meeker AK, Ryu JK, Offerhaus GJA, et al. Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. Modern Pathol. 2009;22(11):1439–45. doi:10.1038/modpathol.2009.114.CrossRef

Kshirsagar M, Jiang W, Shih IM. DNA damage response is prominent in ovarian high-grade serous carcinomas, especially those with Rsf-1 (HBXAP) overexpression. J Oncol. 2012. doi:10.1155/2012/621685.PubMed

10.

Matsuda Y, Wakai T, Kubota M, Osawa M, Takamura M, Yamagiwa S et al. DNA damage sensor γ-H2AX is increased in preneoplastic lesions of hepatocellular carcinoma. Scientific World J. 2013;2013. doi:10.1155/2013/597095.

11.

Marteijn JA, Lans H, Vermeulen W, Hoeijmakers JHJ. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol. 2014;15(7):465–81. doi:10.1038/nrm3822.PubMedCrossRef

12.

Gorgoulis VG, Vassiliou LVF, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434(7035):907–13. doi:10.1038/nature03485.PubMedCrossRef

13.

Sedelnikova OA, Bonner WM. γH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle. 2006;5(24):2909–13.PubMedCrossRef

14.

Seeberg E, Eide L, Bjørås M. The base excision repair pathway. Trends Biochem Sci. 1995;20(10):391–7. doi:10.1016/S0968-0004(00)89086-6.PubMedCrossRef

15.

Dianov GL, Hübscher U. Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res. 2013;41(6):3483–90. doi:10.1093/nar/gkt076.PubMedPubMedCentralCrossRef

16.

Dexheimer ST. DNA repair pathways and mechanisms. In: Mathews AL, Cabarcas MS, Hurt ME, editors. DNA Repair of Cancer Stem Cells. Dordrecht: Springer Netherlands; 2013. p. 19–32.CrossRef

17.

Kim Y-J, Wilson DM. Overview of base excision repair biochemistry. Curr Mol Pharmacol. 2012;5(1):3–13.PubMedPubMedCentralCrossRef

18.

D’Amours D, Desnoyers S, D’Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999;342(2):249–68. doi:10.1042/0264-6021:3420249.PubMedPubMedCentralCrossRef

19.

Schreiber V, Dantzer F, Amé JC, De Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7(7):517–28. doi:10.1038/nrm1963.PubMedCrossRef

20.

Amé JC, Spenlehauer C, De Murcia G. The PARP superfamily. BioEssays. 2004;26(8):882–93. doi:10.1002/bies.20085.PubMedCrossRef

21.

de Murcia G, de Murcia JM. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci. 1994;19(4):172–3. doi:10.1016/0968-0004(94)90280-1.PubMedCrossRef

22.

Lindahl T, Satoh MS, Poirier GG, Klungland A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci. 1995;20(10):405–11. doi:10.1016/S0968-0004(00)89089-1.PubMedCrossRef

23.

de Murcia G, Schreiber V, Molinete M, Saulier B, Poch O, Masson M, et al. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem. 1994;138(1):15–24. doi:10.1007/BF00928438.PubMedCrossRef

24.

El‐Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP‐1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003;31(19):5526–33. doi:10.1093/nar/gkg761.PubMedPubMedCentralCrossRef

25.

Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol. 2005;83(3):354–64. doi:10.1139/o05-038.PubMedCrossRef

26.

Virág L, Szabó C. The therapeutic potential of poly(ADP-Ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3):375–429.PubMedCrossRef

27.

Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. Mol Aspects Med. 2013;34(6):1217–56. doi:10.1016/j.mam.2013.01.006.PubMedCrossRef

28.

Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. from concept to clinic. J Med Chem. 2010;53(12):4561–84. doi:10.1021/jm100012m.PubMedCrossRef

29.

Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293–301. doi:10.1038/nrc2812.PubMedPubMedCentralCrossRef

30.

Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol. 2011;3(6):257–67. doi:10.1177/1758834011417039.PubMedPubMedCentralCrossRef

31.

Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res-DNA Repair. 2000;460(1):1–15. doi:10.1016/S0921-8777(00)00016-1.PubMedCrossRef

32.

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7. http://www.nature.com/nature/journal/v434/n7035/suppinfo/nature03443_S1.html.PubMedCrossRef

33.

Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. http://www.nature.com/nature/journal/v434/n7035/suppinfo/nature03445_S1.html.PubMedCrossRef

34.

Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011;108(8):3406–11. doi:10.1073/pnas.1013715108.PubMedPubMedCentralCrossRef

35.

Sonnenblick A, De Azambuja E, Azim HA, Piccart M. An update on PARP inhibitors - Moving to the adjuvant setting. Nat Rev Clin Oncol. 2015;12(1):27–41. doi:10.1038/nrclinonc.2014.163.PubMedCrossRef

36.

Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Upregulation of poly (ADP-Ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer. 2010;1(8):812–21. doi:10.1177/1947601910383418.PubMedPubMedCentralCrossRef

37.

Bièche I, De Murcia G, Lidereau R. Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. Clin Cancer Res. 1996;2(7):1163–7.PubMed

38.

Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol. 2012;23(5):1156–64. doi:10.1093/annonc/mdr361.PubMedCrossRef

39.

Alanazi M, Pathan AAK, Abduljaleel Z. Association between PARP-1 V762A polymorphism and breast cancer susceptibility in Saudi population. PLoS One. 2013;3:92360.

40.

Galia A, Calogero AE, Condorelli R, Fraggetta F, La Corte A, Ridolfo F et al. PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem. 2012;56(1).

41.

Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Gore L, Liu AK, Foreman NK. PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer. 2009;53(7):1227–30. doi:10.1002/pbc.22141.PubMedCrossRef

42.

Staibano S, Pepe S, Muzio LL, Somma P, Mascolo M, Argenziano G, et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol. 2005;36(7):724–31. doi:10.1016/j.humpath.2005.04.017.PubMedCrossRef

43.

Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):247–54.PubMedCrossRef

44.

McKinnon PJ, Caldecott KW. DNA strand break repair and human genetic disease. Annu Rev Genomics Hum Genet. 2007;8:37–55.PubMedCrossRef

45.

Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ. Defective homologous recombination in human cancers. Cancer Treat Rev. 2012;38(2):89–100.PubMedCrossRef

46.

Krajewska M, Fehrmann RSN, De Vries EGE, van Vugt MATM. Regulators of homologous recombination repair as novel targets for cancer treatment. Front Genet. 2015;6:1–15.CrossRef

47.

Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis. 2010;31(6):955–60.PubMedCrossRef

48.

Renkawitz J, Lademann CA, Jentsch S. Mechanisms and principles of homology search during recombination. Nat Rev Mol Cell Biol. 2014;15(6):369–83.PubMedCrossRef

49.

Bunting SF, Nussenzweig A. End-joining, translocations and cancer. Nat Rev Cancer. 2013;13(7):443–54. doi:10.1038/nrc3537.PubMedCrossRef

50.

O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547–60.PubMedCrossRef

51.

Yan CT, Boboila C, Souza EK, Franco S, Hickernell TR, Murphy M, et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature. 2007;449(7161):478–82.PubMedCrossRef

52.

Kuo LJ, Yang L-X. γ-H2AX - A novel biomarker for DNA double-strand breaks. In Vivo. 2008;22(3):305–9.PubMed

53.

Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. In: Bjergbæk L, editor. DNA Repair Protocols. Totowa: Humana Press; 2012. p. 613–26.CrossRef

54.

Shah K, Boghozian RA, Kartsonaki C, Shah KA, Vallis KA. γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies. Diagn Cytopathol. 2016;44(2):141–6. doi:10.1002/dc.23396.PubMedCrossRef

55.

Banáth JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res. 2003;63(15):4347–50.PubMed

56.

Nakamura AJ, Rao VA, Pommier Y, Bonner WM. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle. 2010;9(2):389–97. doi:10.4161/cc.9.2.10475.PubMedPubMedCentralCrossRef

57.

Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. γH2AX and cancer. Nat Rev Cancer. 2008;8(12):957–67. doi:10.1038/nrc2523.PubMedPubMedCentralCrossRef

58.

Mah LJ, El-Osta A, Karagiannis TC. [gamma]H2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24(4):679–86.PubMedCrossRef

59.

Kusch T, Florens L, Macdonald WH, Swanson SK, Glaser RL, Yates 3rd JR, et al. Acetylation by Tip60 is required for selective histone variant exchange at DNA lesions. Science. 2004;306(5704):2084–7.PubMedCrossRef

60.

Downs JA, Allard S, Jobin-Robitaille O, Javaheri A, Auger A, Bouchard N, et al. Binding of chromatin-modifying activities to phosphorylated histone H2A at DNA damage sites. Mol Cell. 2004;16(6):979–90. doi:10.1016/j.molcel.2004.12.003.PubMedCrossRef

61.

Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864–70. http://www.nature.com/nature/journal/v434/n7035/suppinfo/nature03482_S1.html.PubMedCrossRef

62.

Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007;26(56):7773–9.PubMedCrossRef

63.

Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM. H2AX: functional roles and potential applications. Chromosoma. 2009;118(6):683–92. doi:10.1007/s00412-009-0234-4.PubMedPubMedCentralCrossRef

64.

Cedervall B, Wong R, Albright N, Dynlacht J, Lambin P, Dewey WC. Methods for the quantification of DNA double-strand breaks determined from the distribution of DNA fragment sizes measured by pulsed-field gel electrophoresis. Radiat Res. 1995;143(1):8–16. doi:10.2307/3578920.PubMedCrossRef

65.

Herschleb J, Ananiev G, Schwartz DC. Pulsed-field gel electrophoresis. Nat Protoc. 2007;2(3):677–84. http://www.nature.com/nprot/journal/v2/n3/suppinfo/nprot.2007.94_S1.html.PubMedCrossRef

66.

Collins AR. The comet assay for DNA damage and repair: Principles, applications, and limitations. Appl Biochem Biotech - Part B Mol Biotech. 2004;26(3):249–61. doi:10.1385/MB:26:3:249.

67.

Olive PL, Banáth JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc. 2006;1(1):23–9. doi:10.1038/nprot.2006.5.PubMedCrossRef

68.

Löbrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, et al. γH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle. 2010;9(4):662–9.PubMedCrossRef

69.

Panier S, Boulton SJ. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol. 2014;15(1):7–18. doi:10.1038/nrm3719.PubMedCrossRef

70.

Rizzuto R, Brini M, Pizzo P, Murgia M, Pozzan T. Chimeric green fluorescent protein as a tool for visualizing subcellular organelles in living cells. Curr Biol. 1995;5(6):635–42.PubMedCrossRef

71.

Loewer A, Karanam K, Mock C, Lahav G. The p53 response in single cells is linearly correlated to the number of DNA breaks without a distinct threshold. BMC Biol. 2013;11:114. doi:10.1186/1741-7007-11-114.PubMedPubMedCentralCrossRef

72.

Bekker-Jensen S, Lukas C, Kitagawa R, Melander F, Kastan MB, Bartek J, et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol. 2006;173(2):195–206. doi:10.1083/jcb.200510130.PubMedPubMedCentralCrossRef

73.

Hilario J, Amitani I, Baskin RJ, Kowalczykowski SC. Direct imaging of human Rad51 nucleoprotein dynamics on individual DNA molecules. Proc Natl Acad Sci U S A. 2009;106(2):361–8. doi:10.1073/pnas.0811965106.PubMedPubMedCentralCrossRef

74.

Li W, Li F, Huang Q, Shen J, Wolf F, He Y, et al. Quantitative, noninvasive imaging of radiation-induced DNA double-strand breaks in vivo. Cancer Res. 2011;71(12):4130–7. doi:10.1158/0008-5472.CAN-10-2540.PubMedPubMedCentralCrossRef

75.

Williams TM, Nyati S, Ross BD, Rehemtulla A. Molecular imaging of the ATM kinase activity. Int J Radiat Oncol. 2013;86(5):969–77. doi:10.1016/j.ijrobp.2013.04.028.CrossRef

76.

Tu Z, Chu W, Zhang J, Dence CS, Welch MJ, Mach RH. Synthesis and in vivo evaluation of [11C]PJ34, a potential radiotracer for imaging the role of PARP-1 in necrosis. Nucl Med Biol. 2005;32(5):437–43. doi:10.1016/j.nucmedbio.2005.03.001.PubMedCrossRef

77.

Carlucci G, Carney B, Brand C, Kossatz S, Irwin CP, Carlin SD, et al. Dual-modality optical/PET imaging of PARP1 in glioblastoma. Mol Imaging Biol. 2015;17(6):848–55. doi:10.1007/s11307-015-0858-0.PubMedPubMedCentralCrossRef

78.

Carney B, Carlucci G, Salinas B, Di Gialleonardo V, Kossatz S, Vansteene A, et al. Non-invasive PET imaging of PARP1 expression in glioblastoma models. Mol Imaging Biol. 2015. doi:10.1007/s11307-015-0904-y.PubMedPubMedCentral

79.

Edmonds CE, Makvandi M, Lieberman BP, Xu K, Zeng C, Li S, et al. [18F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. Am J Nucl Med Mol Imaging. 2016;6(1):94–101.PubMedPubMedCentral

80.

Zhou D, Chu W, Xu J, Jones LA, Peng X, Li S, et al. Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorg Med Chem. 2014;22(5):1700–7. doi:10.1016/j.bmc.2014.01.019.PubMedPubMedCentralCrossRef

81.

Keliher EJ, Reiner T, Turetsky A, Hilderbrand SA, Weissleder R. High-yielding, two-step 18F labeling strategy for 18F-PARP1 inhibitors. ChemMedChem. 2011;6(3):424–7. doi:10.1002/cmdc.201000426.PubMedCrossRef

82.

Reiner T, Keliher EJ, Earley S, Marinelli B, Weissleder R. Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Angew Chem Int Ed. 2011;50(8):1922–5. doi:10.1002/anie.201006579.CrossRef

83.

Reiner T, Lacy J, Keliher EJ, Yang KS, Ullal A, Kohler RH, et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia. 2012;14:169–77.PubMedPubMedCentralCrossRef

84.

Riss PJ, Soskic V, Schrattenholz A, Roescha F. Synthesis and radiosynthesis of N5-[18F]fluoroethyl- Pirenzepine and its metabolite N5-[18F]fluoroethyl-LS 75. J Labelled Comp Radiopharm. 2009;52(14):576–9. doi:10.1002/jlcr.1687.

85.

Zmuda F, Malviya G, Blair A, Boyd M, Chalmers AJ, Sutherland A, et al. Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo. J Med Chem. 2015;58(21):8683–93. doi:10.1021/acs.jmedchem.5b01324.PubMedCrossRef

86.

Salinas B, Irwin CP, Kossatz S, Bolaender A, Chiosis G, Pillarsetty N et al. Radioiodinated PARP1 tracers for glioblastoma imaging. Eur J Nucl Med Mol Imaging Res. 2015;5(1). doi:10.1186/s13550-015-0123-1.

87.

Menear KA, Adcock C, Boulter R, Cockcroft X-L, Copsey L, Cranston A, et al. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51(20):6581–91. doi:10.1021/jm8001263.PubMedCrossRef

88.

Makvandi M, Xu K, Lieberman BP, Anderson R-C, Effron SS, Winters HD, et al. A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP inhibitor therapy. Cancer Res. 2016;76(15):4516.PubMedCrossRef

89.

Anderson R-C, Makvandi M, Xu K, Lieberman BP, Zeng C, Pryma DA, et al. Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo. Nucl Med Biol. 2016. doi:10.1016/j.nucmedbio.2016.08.007.

90.

Giunta S, Belotserkovskaya R, Jackson SP. DNA damage signaling in response to double-strand breaks during mitosis. J Cell Biol. 2010;190(2):197–207. doi:10.1083/jcb.200911156.PubMedPubMedCentralCrossRef

91.

Nelson G, Buhmann M, Von Zglinicki T. DNA damage foci in mitosis are devoid of 53BP1. Cell Cycle. 2009;8(20):3379–83.PubMedCrossRef

92.

Kersemans V, Kersemans K, Cornelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr Pharm Des. 2008;14(24):2415–27. doi:10.2174/138161208785777432.PubMedCrossRef

93.

Kersemans V, Cornelissen B. Targeting the tumour: cell penetrating peptides for molecular imaging and radiotherapy. Pharmaceuticals. 2010;3(3):600–20. doi:10.3390/ph3030600.PubMedPubMedCentralCrossRef

94.

Zhao M, Weissleder R. Intracellular cargo delivery using tat peptide and derivatives. Med Res Rev. 2004;24(1):1–12. doi:10.1002/med.10056.PubMedCrossRef

95.

Vives E. Cellular utake of the Tat peptide: an endocytosis mechanism following ionic interactions. J Mol Recogn. 2003;16(5):265–71. doi:10.1002/jmr.636.CrossRef

96.

Mishra A, Lai GH, Schmidt NW, Sun VZ, Rodriguez AR, Tong R, et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc Natl Acad Sci U S A. 2011;108(41):16883–8. doi:10.1073/pnas.1108795108.PubMedPubMedCentralCrossRef

97.

Ziegler A, Nervi P, Dürrenberger M, Seelig J. The cationic cell-penetrating peptide CPPTAT derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence. Biochemistry. 2005;44(1):138–48. doi:10.1021/bi0491604.PubMedCrossRef

98.

Brooks H, Lebleu B, Vivès E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev. 2005;57(4):559–77. doi:10.1016/j.addr.2004.12.001.PubMedCrossRef

99.

Jones SW, Christison R, Bundell K, Voyce CJ, Brockbank SMV, Newham P, et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol. 2005;145(8):1093–102. doi:10.1038/sj.bjp.0706279.PubMedPubMedCentralCrossRef

100.

Pan L, He Q, Liu J, Chen Y, Ma M, Zhang L, et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J Am Chem Soc. 2012;134(13):5722–5. doi:10.1021/ja211035w.PubMedCrossRef

101.

Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A. 2001;98(15):8786–91. doi:10.1073/pnas.151247498.PubMedPubMedCentralCrossRef

102.

Pang H-B, Braun GB, Ruoslahti E. Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides. Sci Adv. 2015;1(10). doi:10.1126/sciadv.1500821.

103.

Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. (0021–9258 (Print)).

104.

Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release. 2005;102(1):247–53. doi:10.1016/j.jconrel.2004.10.018.PubMedCrossRef

105.

Kawaguchi Y, Takeuchi T, Kuwata K, Chiba J, Hatanaka Y, Nakase I, et al. Syndecan-4 is a receptor for clathrin-mediated endocytosis of arginine-rich cell-penetrating peptides. Bioconjugate Chem. 2016;27(4):1119–30. doi:10.1021/acs.bioconjchem.6b00082.CrossRef

106.

Ferrari A, Pellegrini V, Arcangeli C, Fittipaldi A, Giacca M, Beltram F. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol Ther. 2003;8(2):284–94.PubMedCrossRef

107.

Truant R, Cullen BR. The arginine-rich domains present in human immunodeficiency virus Type 1 Tat and Rev function as direct importin β-dependent nuclear localization signals. Mol Cell Biol. 1999;19(2):1210–7. doi:10.1128/mcb.19.2.1210.PubMedPubMedCentralCrossRef

108.

Rayne F, Debaisieux S, Yezid H, Lin YL, Mettling C, Konate K, et al. Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J. 2010;29(8):1348–62. doi:10.1038/emboj.2010.32.PubMedPubMedCentralCrossRef

109.

Cornelissen B, McLarty K, Kersemans V, Scollard DA, Reilly RM. Properties of [111In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. Nucl Med Biol. 2008;35(1):101–10. doi:10.1016/j.nucmedbio.2007.09.007.PubMedCrossRef

110.

Cornelissen B, Kersemans V, Darbar S, Thompson J, Shah K, Sleeth K, et al. Imaging DNA damage in vivo using γH2AX-targeted immunoconjugates. Cancer Res. 2011;71(13):4539–49. doi:10.1158/0008-5472.CAN-10-4587.PubMedPubMedCentralCrossRef

111.

Cornelissen B, Able S, Kartsonaki C, Kersemans V, Allen PD, Cavallo F, et al. Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer. J Nucl Med. 2014;55(12):2026–31. doi:10.2967/jnumed.114.142083.PubMedCrossRef

112.

Knight JC, Topping C, Mosley M, Kersemans V, Falzone N, Fernández-Varea JM, et al. PET imaging of DNA damage using 89Zr-labelled anti-γH2AX-TAT immunoconjugates. Eur J Nucl Med Mol Imaging. 2015;42(11):1707–17. doi:10.1007/s00259-015-3092-8.PubMedCrossRef

113.

Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzym Regul. 2001;41(1):189–207. doi:10.1016/S0065-2571(00)00013-3.CrossRef

114.

Cornelissen B, Waller A, Able S, Vallis KA. Molecular radiotherapy using cleavable radioimmunoconjugates that target eGFR and γH2AX. Mol Cancer Ther. 2013;12(11):2472–82. doi:10.1158/1535-7163.PubMedCrossRef

115.

Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med. 2010;40(3):167–81. doi:10.1053/j.semnuclmed.2009.12.005.PubMedPubMedCentralCrossRef

116.

Knight JC, Cornelissen B. Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. Am J Nucl Med Mol Imaging. 2014;4(2):96–113.PubMedPubMedCentral

Title: Imaging the DNA damage response with PET and SPECT
Authors: James C. Knight
Sofia Koustoulidou
Bart Cornelissen
Publication date: 01-06-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3604-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Imaging the DNA damage response with PET and SPECT

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2017

Post-treatment PET/CT and p16 status for predicting treatment outcomes in locally advanced head and neck cancer after definitive radiation

The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma

Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option

An update on the role of PET/CT and PET/MRI in ovarian cancer

Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers

PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans